Ann: Botanix to Present at Euroz Hartleys Conference, page-31

Whilst I agree with you and the raises have been disappointing, we are entering a whole new phase here, being commercialisation.

We are a BIO that will actually make money, unlike many of the stories on the ASX.

With Kaken through Japan we do around 300K subscriptions per annum and I believe Kaken are expanding into China and Korea!

The doors that will open with FDA approval are a lot larger then the average asx punter sees.. remember FDA is the gold standard, so expansion of BOT into Australia and Europe should happen quite easily from there on in, even into South America etc.

This is why BOT dug in and paid off the remaining royalties, to keep a large chunk of the funds.

I only see positives from here on in, just look at the NEU re-rate. So much value to be created here.

Stay strong!